Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

A primer on tumour immunology and prostate cancer immunotherapy.

Ren R, Koti M, Hamilton T, Graham CH, Nayak JG, Singh J, Drachenberg DE, Siemens DR.

Can Urol Assoc J. 2016 Jan-Feb;10(1-2):60-5. doi: 10.5489/cuaj.3418. Review. No abstract available.

2.

(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors.

Gourni E, Canovas C, Goncalves V, Denat F, Meyer PT, Maecke HR.

PLoS One. 2015 Dec 23;10(12):e0145755. doi: 10.1371/journal.pone.0145755. eCollection 2015.

3.

Synthesis and Evaluation of Gd(III) -Based Magnetic Resonance Contrast Agents for Molecular Imaging of Prostate-Specific Membrane Antigen.

Banerjee SR, Ngen EJ, Rotz MW, Kakkad S, Lisok A, Pracitto R, Pullambhatla M, Chen Z, Shah T, Artemov D, Meade TJ, Bhujwalla ZM, Pomper MG.

Angew Chem Int Ed Engl. 2015 Sep 7;54(37):10778-82. doi: 10.1002/anie.201503417. Epub 2015 Jul 23.

4.

A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.

Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AM, Solomon SB, Gönen M, Heller G, Loda M, Nanus DM, Tagawa ST, Feldman JL, Osborne JR, Lewis JS, Reuter VE, Weber WA, Bander NH, Scher HI, Larson SM, Morris MJ.

Clin Cancer Res. 2015 Dec 1;21(23):5277-85. doi: 10.1158/1078-0432.CCR-15-0552. Epub 2015 Jul 14.

PMID:
26175541
5.

DNA vaccination for prostate cancer: key concepts and considerations.

Cole G, McCaffrey J, Ali AA, McCarthy HO.

Cancer Nanotechnol. 2015;6(1):2. Epub 2015 Jul 2.

6.

Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer.

Weineisen M, Simecek J, Schottelius M, Schwaiger M, Wester HJ.

EJNMMI Res. 2014 Dec;4(1):63. doi: 10.1186/s13550-014-0063-1. Epub 2014 Nov 25.

7.

Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors.

Pandit-Taskar N, O'Donoghue JA, Divgi CR, Wills EA, Schwartz L, Gönen M, Smith-Jones P, Bander NH, Scher HI, Larson SM, Morris MJ.

EJNMMI Res. 2015 Apr 29;5:28. doi: 10.1186/s13550-015-0104-4. eCollection 2015.

8.

Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates.

Banerjee SR, Foss CA, Pullambhatla M, Wang Y, Srinivasan S, Hobbs RF, Baidoo KE, Brechbiel MW, Nimmagadda S, Mease RC, Sgouros G, Pomper MG.

J Nucl Med. 2015 Apr;56(4):628-34. doi: 10.2967/jnumed.114.149062. Epub 2015 Feb 26.

9.

Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo.

Wu X, Tai Z, Zhu Q, Fan W, Ding B, Zhang W, Zhang L, Yao C, Wang X, Ding X, Li Q, Li X, Liu G, Liu J, Gao S.

Int J Nanomedicine. 2014 Nov 21;9:5431-40. doi: 10.2147/IJN.S71101. eCollection 2014.

10.

T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression.

Santoro SP, Kim S, Motz GT, Alatzoglou D, Li C, Irving M, Powell DJ Jr, Coukos G.

Cancer Immunol Res. 2015 Jan;3(1):68-84. doi: 10.1158/2326-6066.CIR-14-0192. Epub 2014 Oct 30.

11.

Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.

Westdorp H, Sköld AE, Snijer BA, Franik S, Mulder SF, Major PP, Foley R, Gerritsen WR, de Vries IJ.

Front Immunol. 2014 May 6;5:191. doi: 10.3389/fimmu.2014.00191. eCollection 2014. Review.

12.

Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives.

Viola-Villegas NT, Sevak KK, Carlin SD, Doran MG, Evans HW, Bartlett DW, Wu AM, Lewis JS.

Mol Pharm. 2014 Nov 3;11(11):3965-73. doi: 10.1021/mp500164r. Epub 2014 May 6.

13.

Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases.

Nomura N, Pastorino S, Jiang P, Lambert G, Crawford JR, Gymnopoulos M, Piccioni D, Juarez T, Pingle SC, Makale M, Kesari S.

Cancer Cell Int. 2014 Mar 20;14(1):26. doi: 10.1186/1475-2867-14-26.

14.

Functional prostate-specific membrane antigen is enriched in exosomes from prostate cancer cells.

Liu T, Mendes DE, Berkman CE.

Int J Oncol. 2014 Mar;44(3):918-22. doi: 10.3892/ijo.2014.2256. Epub 2014 Jan 10.

15.

Immune response to sipuleucel-T in prostate cancer.

Thara E, Dorff TB, Averia-Suboc M, Luther M, Reed ME, Pinski JK, Quinn DI.

Cancers (Basel). 2012 Apr 18;4(2):420-41. doi: 10.3390/cancers4020420.

16.

Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.

Baiz D, Hassan S, Choi YA, Flores A, Karpova Y, Yancey D, Pullikuth A, Sui G, Sadelain M, Debinski W, Kulik G.

Neoplasia. 2013 Oct;15(10):1172-83.

17.

Translational Molecular Imaging of Prostate Cancer.

Kiess AP, Cho SY, Pomper MG.

Curr Radiol Rep. 2013 Sep 1;1(3):216-226.

18.

A novel model for evaluating therapies targeting human tumor vasculature and human cancer stem-like cells.

Burgos-Ojeda D, McLean K, Bai S, Pulaski H, Gong Y, Silva I, Skorecki K, Tzukerman M, Buckanovich RJ.

Cancer Res. 2013 Jun 15;73(12):3555-65. doi: 10.1158/0008-5472.CAN-12-2845. Epub 2013 Apr 10.

19.

PSMA as a target for radiolabelled small molecules.

Eder M, Eisenhut M, Babich J, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):819-23. doi: 10.1007/s00259-013-2374-2. No abstract available.

20.

Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen.

Chen Y, Pullambhatla M, Banerjee SR, Byun Y, Stathis M, Rojas C, Slusher BS, Mease RC, Pomper MG.

Bioconjug Chem. 2012 Dec 19;23(12):2377-85. doi: 10.1021/bc3003919. Epub 2012 Dec 4.

Items per page

Supplemental Content

Write to the Help Desk